The Pulse of the Pharmaceutical Industry
FDA Expands Approval For Pfizer Cancer Drug Sutent
Mylan Chops Another 200 To 300 Jobs
FDA Approves AstraZeneca Severe Asthma Drug Fasenra
J Price Set At $373,000
FDA Approves Roche Hemophilia Drug Hemlibra
Biogen Throws Another $200 Million At Aducanumab In Amended Deal With Neurimmune
Boehringer, MiNA Therapeutics Forge NASH Deal
Astellas, Universal Cells Announce Collaboration Utilizing Universal Donor Cell Technology
After years of hope and hype, Bristol-Myers Squibb’s centerpiece immuno-oncologic Opdivo is delivering the dollars.
New CEO David Ricks took over Lilly as the company continues to climb out of its post-Cymbalta/Zyprexa rut.
With proven worldwide commercial capabilities and a robust product pipeline, Johnson & Johnson is firmly positioned to continue generating strong, long-term, sustainable growth.
Easily the fastest grower in Merck’s portfolio, the oncology drug Keytruda is piling up dollars and indications at an impressive rate.
Now on its seventh CEO in the last 10 years and in danger of losing its most valuable branded product, Teva is searching for answers.
With sales of Harvoni and Sovaldi falling off, Gilead welcomed two new blockbusters to the company’s portfolio in 2016.
Amgen is featuring an unprecedented collection of new product offerings, including the first-ever biosimilar cancer treatment to receive U.S. marketing clearance.
Sanofi has faith in strategic plans to get the company to new heights despite continued impact from patent expirations.
Pfizer is overcoming patent expirations by developing a steady new stream of products.
Alexion Wins Expanded Approval For Blockbuster Drug Soliris
Merck To Cut 1,800 Jobs, Add 960 In Chronic Care
Novartis Showcases Four Potential Blockbusters From Late-Stage Pipeline
Drugmaker Novo Nordisk Warns Of U.S. Legislation, Cautious On 2018
Although patent expirations continue to depress revenue, AstraZeneca executives believe in the pipeline.
Management set out a series of new priorities to 2020 to improve innovation, performance and trust in GlaxoSmithKline.
2017 is serving as another challenging year for Novartis as the company continues to work through the Gleevec/Glivec patent expirations that began in 2016, but management is confident that a new phase of growth will start in 2018.
While the world’s leading prescription drug Humira still accounts for the majority of AbbVie’s revenue, plenty else is bubbling up at the almost-five-year-old company.
For Bayer, the acquisition of Monsanto is intended to build its Crop Science division; meanwhile two significant approvals and two new hires enhance progress in oncology.
Roche’s Pharmaceuticals and Diagnostics Divisions continue to generate strong performances significantly driven by new product launches, including four new oncology treatments and the company’s first cancer immunotherapy medicine.
Novo Nordisk executives believe that the company is on a path that will create growth in 2017 and beyond.